Clinical Trial Update: ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update comparing ASK120067 to Gefitinib as first-line treatment for EGFR-mutant locally advanced or metastatic non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ASK120067
• Gefitinib (Gefitinib)

Snippet

Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Conditions: Locally Advanced or Metastatic NSCLC | Phase 3 | Status: ACTIVE_NOT_RECRUITING